Showing 5381-5390 of 5771 results for "".
- Recipients of the 2018 OWL Awards Recognized for Advancing Diversity in Ophthalmology Leadershiphttps://modernod.com/news/recipients-of-the-2018-owl-awards-recognized-for-advancing-diversity-in-ophthalmology-leadership/2479662/OWL: Advancing Diversity in Leadership (OWL) announced the winners of the 2018 OWL Awards at the organization’s Signature Event, which was held October 28 in Chicago during the annual meeting of the American Academy of Ophthalmology (AAO 2018). OWL presents the awards each year to those who best
- Santen Expands Research and Development Leadership Teamhttps://modernod.com/news/santen-expands-research-and-development-leadership-team/2479666/Santen announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Opternative Secures $9M in Most Recent Round of Fundinghttps://modernod.com/news/opternative-secures-9m-in-most-recent-round-of-funding/2479683/Opternative announced it has secured $9 million in its latest round of funding. The round of financing was led by Trust Ventures and Pritzker Group Venture Capital, with an additional investment from existing investor Jump Capital. Opternative will use the fun
- Study Demonstrates Galimedix Therapeutics’ MRZ-99030 Eye Drops Neutralize the Reproduction of Misfolded Amyloid-Betahttps://modernod.com/news/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-eye-drops-neutralizes-the-reproduction-of-misfolded-amyloid-beta/2479684/Galimedix Therapeutics announced the results of a new study at the Society for Neuroscience conference demonstrating that a single application of the investigational compound MRZ-99030, also known as GAL-101, causes sustained prevention of misfolded amyloid beta molecules from aggregating into to
- CooperVision Forum Gathers Global Experts in Childhood Myopia, Identifies Improved Opportunities to Assess and Manage the Conditionhttps://modernod.com/news/coopervision-forum-gathers-global-experts-in-childhood-myopia-identifies-improved-opportunities-to-assess-and-manage-the-condition/2479685/A distinguished panel of global authorities in myopia management gathered this week in Texas, on the eve of the American Academy of Optometry (AAOptom) annual meeting, seeking ways to help eye care professionals better assess and manage the growing epidemic among children. The Myopia Management E
- Two Studies Measure Performance of Acuvue Oasys with Transitions Light Intelligent Technology Contact Lenseshttps://modernod.com/news/two-studies-measure-performance-of-acuvue-oasys-with-transitions-light-intelligent-technology-contact-lenses/2479693/Johnson & Johnson Vision announced that data from two new studies on the visual effects of photochromic contact lenses were presented at the 2018 American Academy of Optometry Annual Meeting in San Antonio. These are the first scientific presentations focused on photochromic contact lens tech